Market Place
Sourcing Support
HighField Biopharma HF1K16 Shows Safe And Efficacy In Metastatic Cancers
18 Sep 2024 //
PHARMABIZ
HighField Biopharma`s HF1K16 Shows Safety In Phase 1 Cancer Trial
16 Sep 2024 //
BUSINESSWIRE
HighField Bio Files IND for HF50 Clinical Trial to Treat Solid Tumor Cancers
03 Sep 2024 //
BUSINESSWIRE
HighField Biopharma HFG1 shows potential as longer-acting GLP-1R agonist.
24 Jun 2024 //
BUSINESSWIRE
HighField: HFK1 Immunoliposome May Top Antibody-Drug Conjugates At ASCO
28 May 2024 //
BUSINESSWIRE
HighField Presents Diabetes GLP-1R Agonist Preclinical Data At ADA
21 May 2024 //
BUSINESSWIRE
HighField Abstracts at ASCO 2024 Annual Meeting
24 Apr 2024 //
BUSINESSWIRE
HighField HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe
08 Jan 2024 //
BUSINESSWIRE
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1
18 Dec 2023 //
BUSINESSWIRE
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16
23 Oct 2023 //
BUSINESSWIRE
HighField Bio Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16
17 Jul 2023 //
BUSINESSWIRE
HighField Bio Receives US FDA IND Clearance for Phase 1 Trial of HF158K1
13 Jun 2023 //
BUSINESSWIRE
HighField’s HF1K16 Shows Promise in Patients with Refractory Glioblastoma
31 May 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.